Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Core Insights - Wave Life Sciences announced the acceptance of a late-breaking oral presentation of data from its RestorAATion-2 clinical trial of WVE-006 at the ATS conference in May 2026, which will include data from both the 400 mg multidose cohort and the 600 mg single dose cohort [1][2] Company Overview - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines, aiming to transform human health through its innovative RNA-targeting modalities [3] - The company's pipeline includes programs for alpha-1 antitrypsin deficiency (WVE-006), obesity (WVE-007), and PNPLA3 I148M liver disease (WVE-008), along with clinical programs in Duchenne muscular dystrophy and Huntington's disease [3] Clinical Trial Details - The RestorAATion-2 trial focuses on WVE-006, a GalNAc-conjugated RNA editing oligonucleotide targeting alpha-1 antitrypsin deficiency, a single-gene disorder that affects both lung and liver health [2] - The late-breaking oral presentation will be held on May 18, 2026, featuring Kenneth R. Chapman as the presenter [3]